Investigation of reduction process and related impurities in ezetimibe

被引:4
作者
Zhang, Dengfeng [1 ]
Su, Jiangtao [1 ]
机构
[1] Hubei Univ Technol, Dept Pharmaceut Engn, Wuhan 430068, Hubei, Peoples R China
关键词
Ezetimibe; Quality by design (QbD); Impurity; Synthesis; Characterization; INTERMEDIATE;
D O I
10.1016/j.jpba.2015.01.008
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
During the synthesis of ezetimibe bulk drug, research for the impurities which especially come from the last two steps of synthetic route is of great significance for the quality by design (QbD) concept. The design spaces of last two steps of reduction reaction were established. The critical parameters were discussed under the QbD concept, which have noticeable impact on the impurity profile such as the new process related impurities mentioned in this paper. Three novel reduction process related impurities were prepared by designed synthetic route and co-injected with ezetimibe sample for identification. These novel process related impurities were also detected in different laboratory batches of ezetimibe bulk drug and characterized using MS, H-1, C-13, 2D NMR and IR techniques. The synthesis, isolation, identification, structural elucidation and formation of impurities were also discussed in detail. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 14 条
[1]   Process for preparing Ezetimibe intermediate by enantioselective CBS catalyzed ketone reduction with BH3-DEA prepared in situ [J].
Bertrand, Blandine ;
Durassier, Sonia ;
Frein, Stephane ;
Burgos, Alain .
TETRAHEDRON LETTERS, 2007, 48 (12) :2123-2125
[2]   Physicochemical characterization of ezetimibe and its impurities [J].
Filip, Katarzyna ;
Bankowski, Krzysztof ;
Sidoryk, Katarzyna ;
Zagrodzka, Joanna ;
Laszcz, Marta ;
Trzcinska, Kinga ;
Szyprowska, Anna ;
Cmoch, Piotr ;
Maruszak, Wioleta .
JOURNAL OF MOLECULAR STRUCTURE, 2011, 991 (1-3) :162-170
[3]   Process for preparing Ezetimibe intermediate by an acid enhanced chemo- and enantioselective CBS catalyzed ketone reduction [J].
Fu, XY ;
McAllister, TL ;
Thiruvengadam, TK ;
Tann, CH ;
Su, D .
TETRAHEDRON LETTERS, 2003, 44 (04) :801-804
[4]  
Gajjar A.K., 2001, J PHARM BIOMED ANAL, V55, P225
[5]  
Gibson M., 2001, PHARM PREFORMULATION, P295
[6]  
Heek MV, 2001, BRIT J PHARMACOL, V134, P409
[7]  
ICH Q8-Food and Drug Administration CDER, 2006, GUID IND Q8 PHARM DE
[8]  
International Conference on Harmonization, 2006, ICH GUID Q3AR2 IMP N
[9]   Structural elucidation of a process-related impurity in ezetimibe by LC/MS/MS and NMR [J].
Raman, Bhanu ;
Sharma, Brajesh A. ;
Butala, Rahul ;
Ghugare, Pradeep D. ;
Kumar, Ashok .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2010, 52 (01) :73-78
[10]  
Rosenblum S.B., 1995, [No title captured], Patent No. [WO 9508532A1, 9508532, WO 9508532]